FRIDAY, Jan. 16, 2026 — Treatment-resistant depression might be eased using an implant that sends electrical pulses to one of the body’s major nerve clusters, a new study says. The implant, placed under the skin in the chest, sends carefully calibrated electrical pulses to the left vagus nerve — a major conduit between the brain and internal organs. More than 20% of all patients treated with the implant had essentially no symptoms of depression after two years, researchers reported Jan. 13 in t

FRIDAY, Jan. 16, 2026 -- Among men, but not women, with cannabis use disorder (CUD) seeking treatment, varenicline with medical management results in decreased cannabis use, according to a study published online Jan. 15 in Addiction . Aimee L. McRae-Clark, Pharm.D., from the Medical University of South Carolina in Charleston, and colleagues conducted a phase 2, randomized, placebo-controlled trial in two outpatient research clinics to examine the efficacy of varenicline with medical management f

Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and Drug Administration (FDA) by year end Interim analysis requested by FDA demonstrated statistically significant longer duration of complete response with ANKTIVA + BCG Expanded access program (EAP) of recombinant BCG proceeding well CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBR

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care Novartis plans to submit to health authorities globally starting in early 2026 Ianalumab has potential to become first targeted treatment for this autoimmune disease with significant unmet need Basel, January 16, 2026 – Nov

FRIDAY, Jan. 16, 2026 -- About one-third of health care professionals who are aware of subcutaneous depot- medroxyprogesterone acetate (DMPA-SC) for user administration actively prescribe it, according to a study published online Jan. 8 in O&G Open . Chase Clark, from the University of California, Davis, in Sacramento, and colleagues conducted a mixed-methods study of 422 surveys and 34 interviews with family planning experts to identify facilitators and barriers to prescribing DMPA-SC for user

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Jan. 16, 2026-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acqui

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Com

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best efforts registered direct offering ("Offering") of 6,400,000 ordinary shares at an Offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. T

Toronto, Ontario--(News - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter") as the sole underwriter and sole bookrunner pursuant to which the Underwriter has agreed to purchase for resale 10,384,616